

# De novo designed proteins neutralize lethal snake venom toxins

<https://doi.org/10.1038/s41586-024-08393-x>

Received: 8 May 2024

Accepted: 13 November 2024

Published online: 15 January 2025

Open access

 Check for updates

Susana Vázquez Torres<sup>1,2,3</sup>, Melisa Benard Valle<sup>4</sup>, Stephen P. Mackessy<sup>5</sup>, Stefanie K. Menzies<sup>6,7,8</sup>, Nicholas R. Casewell<sup>6,7</sup>, Shirin Ahmadi<sup>4</sup>, Nick J. Burlet<sup>4</sup>, Edin Muratspahic<sup>1,2</sup>, Isaac Sappington<sup>1,2,3</sup>, Max D. Overath<sup>4</sup>, Esperanza Rivera-de-Torre<sup>4</sup>, Jann Ledergerber<sup>4</sup>, Andreas H. Laustsen<sup>4</sup>, Kim Bodduum<sup>9</sup>, Asim K. Bera<sup>1,2</sup>, Alex Kang<sup>1,2</sup>, Evans Brackenbrough<sup>1,2</sup>, Iara A. Cardoso<sup>6</sup>, Edouard P. Crittenden<sup>6</sup>, Rebecca J. Edge<sup>10</sup>, Justin Decarreau<sup>1,2</sup>, Robert J. Ragotte<sup>1,2</sup>, Arvind S. Pillai<sup>1,2</sup>, Mohamad Abedi<sup>1,2</sup>, Hannah L. Han<sup>1,2</sup>, Stacey R. Gerben<sup>1,2</sup>, Analisa Murray<sup>1,2</sup>, Rebecca Skotheim<sup>1,2</sup>, Lynda Stuart<sup>1,2</sup>, Lance Stewart<sup>1,2</sup>, Thomas J. A. Fryer<sup>4,11</sup>, Timothy P. Jenkins<sup>4</sup>✉ & David Baker<sup>1,2,12</sup>✉


Snakebite envenoming remains a devastating and neglected tropical disease, claiming over 100,000 lives annually and causing severe complications and long-lasting disabilities for many more<sup>1,2</sup>. Three-finger toxins (3FTx) are highly toxic components of elapid snake venoms that can cause diverse pathologies, including severe tissue damage<sup>3</sup> and inhibition of nicotinic acetylcholine receptors, resulting in life-threatening neurotoxicity<sup>4</sup>. At present, the only available treatments for snakebites consist of polyclonal antibodies derived from the plasma of immunized animals, which have high cost and limited efficacy against 3FTxs<sup>5–7</sup>. Here we used deep learning methods to de novo design proteins to bind short-chain and long-chain  $\alpha$ -neurotoxins and cytotoxins from the 3FTx family. With limited experimental screening, we obtained protein designs with remarkable thermal stability, high binding affinity and near-atomic-level agreement with the computational models. The designed proteins effectively neutralized all three 3FTx subfamilies in vitro and protected mice from a lethal neurotoxin challenge. Such potent, stable and readily manufacturable toxin-neutralizing proteins could provide the basis for safer, cost-effective and widely accessible next-generation antivenom therapeutics. Beyond snakebite, our results highlight how computational design could help democratize therapeutic discovery, particularly in resource-limited settings, by substantially reducing costs and resource requirements for the development of therapies for neglected tropical diseases.

Snakebite envenoming represents a public health threat in many developing regions, notably low-resource settings in sub-Saharan Africa, South Asia, Papua New Guinea and Latin America<sup>2</sup>. With over two million annual cases, snakebites result in 100,000 fatalities and 300,000 permanent disabilities<sup>1</sup>. In 2017, the World Health Organization listed snakebite envenoming as a highest-priority neglected tropical disease<sup>8</sup>. Nonetheless, limited resources have been dedicated to improving the current antivenom treatments<sup>2</sup>. These therapies rely on plasma-derived polyclonal antibodies from hyperimmunized animals, complemented by medical and surgical care<sup>9</sup>. Although instrumental in saving lives, antivenom accessibility is hindered by high production costs and inadequate cold-chain infrastructure in remote areas<sup>9</sup>. Serious adverse effects, including anaphylaxis and pyrogenic reactions, represent additional challenges during antivenom administration<sup>2,10,11</sup>. Furthermore, these treatments are often ineffective in counteracting neurotoxicity

and tissue necrosis owing to suboptimal concentrations of neutralizing antibodies against three-finger toxins (3FTxs)<sup>5–7</sup>. This inefficacy stems from the limited immunogenicity of 3FTxs in antivenom-producing animals, resulting in a failure to elicit a strong antibody response<sup>12</sup>. Additional issues arise because of the delayed administration of antivenom treatment<sup>13</sup>. Antibody<sup>14–21</sup> and non-antibody-based therapeutics<sup>22–28</sup> have been tested in preclinical studies, but the development of these types of molecules requires either immunization of animals or the development of large libraries that require extensive selection, screening and optimization efforts<sup>29</sup>.

We reasoned that de novo design approaches could have advantages over the traditional methods of antivenom development. First, de novo protein design does not rely on animal immunization and yields proteins that can be manufactured using recombinant DNA technology, thereby creating a source for the continuous production of products

<sup>1</sup>Department of Biochemistry, University of Washington, Seattle, WA, USA. <sup>2</sup>Institute for Protein Design, University of Washington, Seattle, WA, USA. <sup>3</sup>Graduate Program in Biological Physics, Structure and Design, University of Washington, Seattle, WA, USA. <sup>4</sup>Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark. <sup>5</sup>Department of Biological Sciences, University of Northern Colorado, Greeley, CO, USA. <sup>6</sup>Centre for Snakebite Research & Interventions, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK. <sup>7</sup>Centre for Drugs & Diagnostics, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK. <sup>8</sup>Biomedical & Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, UK. <sup>9</sup>Sophion Bioscience, Ballerup, Denmark. <sup>10</sup>Department of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK. <sup>11</sup>Media Lab, Massachusetts Institute of Technology, Cambridge, MA, USA. <sup>12</sup>Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA. ✉e-mail: tpaje@dtu.dk; dabaker@uw.edu



**Fig. 1 | Targets of 3FTxs.** **a**, Structure of 3FTx<sup>59</sup> (Protein Data Bank (PDB) 1QKD). Highly conserved cysteine residues are highlighted in sticks, and each of the three fingers is indicated (I–III). **b**, Representation of type IA cytotoxin<sup>60</sup> (dark pink) (PDB 5NQ4) interacting with a lipid bilayer. **c**, Muscle acetylcholine (ACh) (torpedo) receptor (light blue) (PDB 7Z14)<sup>36</sup>. The ACh-binding site is depicted in violet. Left inset: close-up of the acetylcholine-binding protein (AChBP) (teal) (PDB 3WIP) bound to ACh<sup>61</sup> (violet). A set of aromatic residues form a cage around the neurotransmitter. Middle inset: close-up of α-cobratoxin (dark purple) blocking access to the ACh-binding site in AChBP (teal) (PDB 1Y15)<sup>44</sup>.


A molecule of ACh is depicted to illustrate its binding site. Right inset: close-up of ScNtx (dark blue) blocking access to the ACh-binding site in the torpedo receptor (light blue) (PDB 7Z14)<sup>36</sup>. A molecule of ACh is depicted to illustrate its binding site. **d**, Schematic showing α-cobratoxin binder design using RFdiffusion. Starting from a random distribution of residues around the specified β-strands in the target toxin (dark purple), successive RFdiffusion denoising steps progressively removed the noise leading at the end of the trajectory to a folded structure interacting with α-cobratoxin β-strands. Schematics in **a–c** were created using BioRender (<https://biorender.com>).

with limited batch-to-batch variation. Second, computational design enables the creation of binding proteins with high affinity and specificity without needing extensive experimental screening programmes that often rely on pure toxins, which can be challenging to isolate from whole venoms or generate via recombinant expression<sup>30</sup>. Third, the small size of the designed proteins could offer enhanced tissue penetration<sup>31</sup> compared to large antibodies, enabling rapid toxin neutralization and thereby being more effective in neutralizing local tissue damage. Fourth, designed proteins can have high thermal stability<sup>32</sup> and can be produced using low-cost microbial fermentation strategies, which could help enable the development and deployment of new antivenom therapeutics at reduced cost<sup>33</sup>. Hence, we used the deep learning-based RFdiffusion method<sup>32</sup> to design antivenoms for short-chain and long-chain α-neurotoxins and cytotoxins from the 3FTx snake venom toxin family. We explored the design of binders for both individual natural toxins

and consensus toxins representing a family of toxin molecules because binders to the latter could have broader neutralization activity.

### Design of α-neurotoxin-binding proteins

α-Neurotoxins, a prominent subclass of 3FTxs, adopt a multistranded β-structure with three extended loops protruding from a hydrophobic compact core stabilized by highly conserved disulfide bridges<sup>34,35</sup> (Fig. 1a). Short-chain and long-chain α-neurotoxins differ in their length and number of disulfide bonds. Despite sequence homology, α-neurotoxins have distinct pharmacological profiles across nicotinic acetylcholine receptor (nAChR) subtypes; short-chain and long-chain α-neurotoxins inhibit muscle-type nAChRs, but only long-chain α-neurotoxins strongly bind to neuronal α7-nAChRs<sup>36</sup> (Fig. 1c). The venoms of many elapid snake species derive their lethal effects from



**Fig. 2 | Experimental characterization of 3FTx-binding proteins.** **a**, Design models of protein binders (grey) bound to their 3FTx targets (dark blue, ScNtx; dark purple,  $\alpha$ -cobratoxin; dark pink, consensus cytotoxin). **b**, SEC traces of purified proteins. mAU, milli-absorbance units. **c**, SPR-binding affinity


measurements. Coloured solid lines represent fits using the heterogeneous ligand model, with the dissociation constant ( $K_d$ ) values derived from these fits. RU, response units. **d**, CD data confirmed the presence of an  $\alpha\beta$ -secondary structure in the 3FTx-binding proteins and their thermal stability (inset).  $\theta$ , molar ellipticity.

these toxins, and it is crucial to neutralize both types of  $\alpha$ -neurotoxins to achieve therapeutic efficacy and prevent venom-induced lethality.

To achieve functional neutralization, we focused on binding modes that block neurotoxin binding to nAChRs through steric hindrance. Rather than focusing on the nAChR-binding site like previously discovered antibodies<sup>14,20,21</sup>, we took advantage of recently developed methods which enable the robust design of high affinity binders to polar targets by complementing edge  $\beta$ -strands in the target with geometrically matching edge  $\beta$ -strands in the designed binder (ref. 37; see Methods). RFdiffusion trajectories were carried out conditioned on secondary structure and block adjacency tensors guiding generation towards each exposed (edge)  $\beta$ -strand in each neurotoxin one at a time. Following generation of backbones making extended  $\beta$ -sheets with the targets through these conditioned RFdiffusion denoising trajectories, sequence design was carried out using ProteinMPNN. The resulting designs were filtered on the basis of AlphaFold2 (AF2) initial guess<sup>38</sup> and Rosetta metrics, and the most promising candidates were selected for experimental characterization. Top candidates were selected for in vitro validation on the basis of their ability to interfere with toxin binding to nAChR, guided by structural alignments

comparing the neurotoxin–nAChR complex with and without the designed binder.

We targeted short-chain  $\alpha$ -neurotoxins using a previously designed consensus toxin derived from elapid snakes (ScNtx)<sup>39</sup> as a representative template (Supplementary Fig. 8). Synthetic genes encoding 44 designs targeting ScNtx were screened via yeast surface display, and one candidate was identified to bind ScNtx with a dissociation constant ( $K_d$ ) of 842 nM, as confirmed by bio-layer interferometry (BLI) (Supplementary Fig. 1). Following partial diffusion optimization<sup>40</sup>, 11 of 78 designs had higher affinity than the initial hit (Supplementary Fig. 9), with the best (SHRT) having a binding affinity of 0.9 nM, as determined by surface plasmon resonance (SPR) (Fig. 2c, top row; a very similar value of 0.7 nM was obtained by BLI (Supplementary Fig. 2)). SHRT showed a single monomeric peak in size exclusion chromatography (SEC), characteristic  $\alpha\beta$ -protein circular dichroism (CD) spectra and thermal stability with a melting temperature ( $T_m$ ) of 78 °C (Fig. 2d, top row). Using X-ray crystallography, we determined the structure of the SHRT design in the apo state, which closely matched the computational design model (2.58 Å resolution; 1.04 Å root-mean-square deviation (RMSD)) (Fig. 3a). The binder interacts with loop III of the



**Fig. 3 | Crystal structures of 3FTx-binding proteins closely matched those of the design models. a,** Apo-state crystal structure of SHRT design. Left: hydrogen bonding between the carbonyl oxygen of Cys41 in ScNtx (dark blue) and the side chain of Tyr45 in the SHRT design model (grey). Middle: overlay of the SHRT design model (grey) with crystal structure (wheat). Right: backbone hydrogen bonding between the SHRT design model (grey) and ScNtx (dark blue) β-strands. **b,** Crystal structure of LNG design in complex with α-cobratoxin. Left: cross-interface hydrogen-bond network involving Arg33 in loop II of α-cobratoxin (light purple) and Glu69, Tyr40 and Tyr49 in the LNG crystal structure (wheat). Middle: overlay of the LNG design model (grey) bound to

α-cobratoxin (dark purple) with crystal structure of binder (wheat) bound to toxin (light purple). Right: backbone hydrogen bonding between the crystal structure of the designed binder (wheat) and α-cobratoxin (light purple) β-strands. **c,** Crystal structure of CYTX\_B10 design in complex with *Naja pallida* cytotoxin. Left: cross-interface electrostatic interaction network between loops III and II of *N. pallida* cytotoxin (light pink) and the binder crystal structure (wheat). Middle: overlay of the CYTX\_B10 design model (grey) bound to the toxin (dark pink) with the crystal structure of the binder (wheat) bound to *N. pallida* cytotoxin (light pink). Right: salt bridge between positively charged Lys18 in cytotoxin (light pink) and Asp57 in the binder crystal structure (wheat).

neurotoxin, which is key for the binding of the toxin to muscle-type nAChRs<sup>41</sup> (Fig. 3a). A β-strand in SHRT forms extensive backbone hydrogen bonds with an edge β-strand in the toxin (Fig. 3a, right inset), and tyrosine 45, located on an alpha helix in SHRT, forms a backbone hydrogen bond with cysteine 41 on ScNtx (Fig. 3a, left inset).

As a representative native long-chain α-neurotoxin, we chose α-cobratoxin (P01391) from *Naja kaouthia*, one of the most extensively characterized toxins in the 3FTx family<sup>42</sup> (Fig. 1). Of 42 RFdiffusion designs against α-cobratoxin, one candidate had a binding affinity of 1.3 μM using BLI (Supplementary Fig. 3). Partial diffusion optimization of the binding interface generated 38 designs (Supplementary Fig. 10), the highest affinity of which, LNG, had a  $K_d$  of 1.9 nM, as measured by SPR (Fig. 2c, middle row; BLI yielded a value of 6.7 nM (Supplementary Fig. 4)). CD melting experiments showed a very high thermal stability ( $T_m > 95^\circ\text{C}$ ; Fig. 2d, middle row).

Using X-ray crystallography, we determined the structure of the LNG α-cobratoxin binder in complex with the target, which closely matched the computational design model (2.68 Å resolution; 0.42 Å RMSD over design, 0.61 Å over toxin; there was a slight deviation in the positioning of the toxin relative to the binder). As in the design model,

the binder interacts with the central loop II of the neurotoxin, which is crucial for the interaction of the toxin with muscle-type and neuronal α7-nAChRs<sup>41,43</sup>. This interaction is primarily mediated by backbone hydrogen bonding between the β-strand in LNG and a β-strand in the toxin (Fig. 3b). Arg33, located at the tip of loop II of α-cobratoxin, forms extensive interactions with LNG (Fig. 3b, left inset). This toxin residue also interacts extensively with AChBP<sup>44</sup>.

### Design of cytotoxin-binding proteins

Cytotoxins, a prominent functional group in the 3FTx family found in cobra venoms, exert cytotoxic effects and induce local tissue damage by destabilizing phospholipid membranes<sup>45</sup> (Fig. 1b). Neutralizing these toxins is crucial to prevent severe sequelae, such as limb deformity, amputation and lasting disabilities in snakebite victims<sup>46</sup>.

To target cytotoxins, we hypothesized that relying solely on β-strand pairing interactions might not adequately prevent cytotoxin insertion into membranes because of the critical role of their three-finger loops in membrane interaction and disruption<sup>47–50</sup> (Fig. 1b). Instead, we focused on binding directly to the three-finger loops of the cytotoxin by

generating RFdiffusion-based protein backbones with hotspot residues defined in these regions (Fig. 2a, bottom row). To increase the breadth of neutralization, we targeted a consensus sequence derived from 86 different snake cytotoxins (type IA cytotoxin sub-subfamily; Methods). Following ProteinMPNN and AF2 screening, partial diffusion was used to further optimize the designs with the best metrics. A total of 55 protein designs were recombinantly expressed using *Escherichia coli*, and following SEC purification, 18 designs with monomeric populations were tested in a luminescent cell viability assay. Of these, one protein binder (CYTX) had high solubility, with a single monomeric peak in SEC and high neutralization activity against *Naja pallida* and *Naja nigricollis* whole venoms, known for their high cytotoxin content<sup>51</sup> (Supplementary Fig. 5). The  $K_d$  for the cytotoxin from *N. pallida* was determined to be 271 nM via SPR (Fig. 2c, bottom row). CYTX exhibited a characteristic  $\alpha\beta$ -protein CD spectrum and was thermostable with a  $T_m$  of 61 °C (Fig. 2d, bottom row).

Few designed binders have targeted loops; hence, we sought to solve the crystal structure of CYTX in complex with the *N. pallida* cytotoxin (Fig. 3c). To reduce flexibility to favour crystallization, a disulfide bond was introduced in a flexible loop connecting the  $\beta$ -sheet segment to the two  $\alpha$ -helices of CYTX, yielding a candidate (CYTX\_B10) with improved thermal stability ( $T_m = 70.3$  °C) and monomeric profile during SEC, but a slightly weaker  $K_d$  of 740 nM for *N. pallida* cytotoxin (Supplementary Fig. 6). The structure of CYTX\_B10 in complex with the target closely matched the computational design model (resolution, 2.0 Å; RMSD, 1.32 Å over design and 0.58 Å over toxin), showing extensive electrostatic interactions involving side chain–main chain hydrogen bonds between cytotoxin loops II and III and the CYTX\_B10 binder (Fig. 3c, left inset). The unusual open fold of CYTX\_B10 highlights the power of RFdiffusion to custom generate scaffolds shape-matched with protein targets and the power of proteinMPNN to stabilize structures that violate common rules of protein structure (in this case, lacking a central hydrophobic core).

## In vitro neutralization

We assessed the ability of the designs to functionally neutralize  $\alpha$ -neurotoxins in patch-clamp experiments using a human-derived rhabdomyosarcoma cell line expressing muscle-type nAChRs. When preincubated with ScNtx, the SHRT design achieved complete neutralization at a 1:1 molar ratio (toxin:binder), which was better than the previously characterized ScNtx nanobody (TPL1163\_02\_A01)<sup>52</sup> (Fig. 4a; a control nanobody targeting phospholipase A<sub>2</sub> had no effect). Similarly, the LNG design had a better neutralizing efficacy than a previously characterized  $\alpha$ -cobratoxin nanobody (TPL1158\_01\_C09)<sup>52</sup>, achieving full protection at a 1:1 molar ratio (toxin:binder) (Fig. 4b).

We used a cytotoxicity assay to evaluate the cross-reactivity of the CYTX design against various cobra whole venoms. Immortalized human keratinocytes (N/TERTs) were exposed to venoms from seven different *Naja* species, which previous proteomic analyses suggested primarily consist (approximately 70%) of cytotoxins<sup>53</sup>. Preincubating CYTX with venom (two IC<sub>50</sub> values) at a 1:5 molar ratio (toxin:binder) provided 70–90% protection against venom-induced cytotoxicity (Fig. 4c). Similarly, preincubation of the cytotoxin binder with the isolated cytotoxin from *N. pallida* (two IC<sub>50</sub> values) at a 1:5 molar ratio (toxin:binder) provided 85% protection against cytotoxicity (Fig. 4c). However, preliminary studies indicated that the CYTX design, in 1:1, 1:2.5 and 1:5 molar ratios (toxin:binder), did not significantly decrease the size of the dermonecrotic lesions induced by intradermal *N. nigricollis* venom administration in a murine model<sup>54</sup> (Supplementary Fig. 7). The affinity of CYTX likely needs to be further optimized for full in vivo neutralization of cytotoxins.

## In vivo protection


Given the encouraging in vitro neutralization of our anti-neurotoxin designs, we proceeded to in vivo studies. We determined the mean

lethal dose (LD<sub>50</sub>) values for  $\alpha$ -neurotoxins in male non-Swiss albino mice via intraperitoneal administration;  $\alpha$ -cobratoxin had an LD<sub>50</sub> of 0.098 µg g<sup>-1</sup> and ScNtx had an LD<sub>50</sub> of 0.087 µg g<sup>-1</sup>, in agreement with previous intravenous LD<sub>50</sub> doses of these toxins (0.1 µg g<sup>-1</sup>) (ref. 55). To evaluate the in vivo neutralization efficacy of our neurotoxin-targeting designs, we monitored survival for 24 h post-lethal neurotoxin challenge following the administration of purified toxins (three LD<sub>50</sub> values) (Fig. 4d). The SHRT binder provided complete protection (100%) to mice when preincubated and administered intraperitoneally with the corresponding short-chain neurotoxin at a 1:10 molar ratio of toxin to binder; however, as expected, it did not neutralize the non-target  $\alpha$ -cobratoxin. The LNG binder exhibited comparable efficacy, completely neutralizing  $\alpha$ -cobratoxin but not the non-target ScNtx (Fig. 4d, left). In rescue assays that better mimicked a real-life snakebite scenario, complete protection (100%) was achieved when short-chain or long-chain  $\alpha$ -neurotoxin binders were administered intraperitoneally at a 1:10 molar ratio (toxin:binder) 15 min after a lethal  $\alpha$ -neurotoxin challenge (three LD<sub>50</sub> values) (Fig. 4d, middle). Administering the SHRT binder 30 min after toxin injection also provided 100% protection against ScNtx, whereas the LNG binder conferred 60% protection against  $\alpha$ -cobratoxin (Fig. 4d, right). All of the surviving mice showed no evidence of limb or respiratory paralysis. At a 1:5 molar ratio (toxin:binder), intraperitoneal administration of the SHRT design 15 min after toxin injection (three LD<sub>50</sub> values) resulted in 100% survival, whereas the LNG binder provided 80% protection. Mice injected with the binder alone showed no negative effects at 24 and 48 h post-injection or up to 2 weeks post-injection.

## Discussion

Antivenoms based on animal-derived polyclonal antibodies have long been the cornerstone of snakebite therapy, but their application is hampered by limited efficacy against toxins with low immunogenicity, propensity to cause severe adverse reactions, inherent batch-to-batch variations and high production costs associated with their manufacture<sup>56</sup>. Thus, there has been a search for alternatives, with recombinant human monoclonal antibodies and nanobodies presenting solutions that can help overcome some of these limitations<sup>57</sup>. Our designed neurotoxin binders demonstrate comparable potency to the best immunoglobulin G antibodies and nanobodies reported in the literature<sup>57</sup> and are highly stable and readily producible in microbial systems. Their small size (approximately 100 amino acids) may enable them to penetrate rapidly into deep tissue<sup>31</sup>. More generally, our in silico design approach avoids animal immunization and/or construction and several rounds of selection and/or screening of large libraries, providing a low-cost methodology for the rapid development of toxin binders to the many components of snake venom when structural or sequence data exist for these targets. De novo designed proteins have high stability and are amenable to low-cost manufacturing, which is key to effectively address snakebite envenoming as a neglected tropical disease. From the design perspective, the crystal structure of our cytotoxin binder highlights the ability of RFdiffusion to custom design scaffolds to match almost any target shape and to generate binders to loop regions of proteins. The inhibitory activity of our anti-cytotoxin designs directly supports a hypothesized role for the cytotoxin loops in membrane disruption.

Advancing the field to provide effective solutions for snakebite victims requires a collaborative effort involving the scientific community, pharmaceutical industry, public health systems, and governments<sup>2</sup>. Although traditional antivenoms will likely remain a therapeutic cornerstone in snakebite treatment for the immediate future, our de novo designed binders could potentially be used as fortifying agents to improve the efficacy of antivenoms, which would be particularly beneficial in the treatment of elapid envenomings, in which low-molecular-mass toxins with limited immunogenicity but



**Fig. 4 | In vitro and in vivo efficacy.** **a**, Concentration–response curves comparing SHRT binder and an anti-ScNtx nanobody ( $V_H$ ) efficacy in preventing nAChR blocking by ScNtx at a dose corresponding to the 80% inhibitory concentration ( $IC_{50}$ ). The y axis corresponds to the ACh response in the presence of toxin and design, normalized to full ACh response, and averaged in each group ( $n=16$ ). **b**, Concentration–response curves comparing the efficacy of the LNG binder and anti- $\alpha$ -cobratoxin  $V_H$  in preventing nAChR blocking by one  $IC_{50}$  of  $\alpha$ -cobratoxin. **c**, Neutralization of the cytolytic effects of whole venoms from seven different *Naja* species and isolated cytotoxin by the CYTX binder. Two  $IC_{50}$  values of the whole venom or toxin were preincubated with CYTX at a 1:5 molar ratio (toxin:binder). This ratio was estimated assuming that 70% of the whole venom consists of cytotoxins, on the basis of previous proteomic analyses<sup>53</sup>. Keratinocyte medium was used as a positive control (PC). Triton X-100 was used as a negative control (NC). CYTX binder (B) was used as a PC. (−) denotes two  $IC_{50}$  values of the whole venom without a binder, and

(+) denotes venom incubated with a binder. Experiments were performed in triplicate, and the results are expressed as mean  $\pm$  s.d. **d**, Survival of mice following lethal neurotoxin challenge ( $n=5$ ). At a concentration corresponding to three times the  $LD_{50}$  value of ScNtx or  $\alpha$ -cobratoxin, either were preincubated for 30 min (−30 min) with the corresponding protein binders at a 1:10 ratio and then administered intraperitoneally into groups of five mice. Toxins were administered intraperitoneally following IP administration of binders at 1:10 or 1:5 molar ratios (toxin:binder) either 15 min (+15 min) or 30 min (+30 min) post-toxin injection. Controls included mice that received the toxins alone (C). Specificity was assessed via cross-treatment (CT) experiments, in which non-target binders were preincubated with three  $LD_{50}$  values of ScNtx or  $\alpha$ -cobratoxin and administered intraperitoneally. Signs of toxicity were observed, and deaths were recorded for a period of 24 h. Illustration in **d** created with BioRender (<https://biorender.com>).

high medical importance dominate toxicity and therefore must be neutralized<sup>58</sup>. Beyond fortification, RFdiffusion could be used to generate designs that neutralize other medically relevant toxins, expediting the

formulation of antivenoms with broader species coverage. More generally, as in silico protein design is less resource-intensive than traditional antibody development, our approach could aid in the democratization

of drug design and discovery, enabling researchers in low-income and middle-income countries to better contribute to the development of effective treatments for snakebite envenoming and other neglected tropical diseases.

## Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41586-024-08393-x>.

1. GBD 2019 Snakebite Envenomation Collaborators. Global mortality of snakebite envenoming between 1990 and 2019. *Nat. Commun.* **13**, 6160 (2022).
2. Gutiérrez, J. M. et al. Snakebite envenoming. *Nat. Rev. Dis. Primer* **3**, 17063 (2017).
3. Royte, L. & Sawarkar, A. Snake bite—cytotoxic effects of snake venom: a rare clinical image. *Pan Afr. Med. J.* **44**, 61 (2023).
4. Barber, C. M., Isbister, G. K. & Hodgson, W. C. Alpha neurotoxins. *Toxicon* **66**, 47–58 (2013).
5. Deka, A., Gogoi, A., Das, D., Purkayastha, J. & Doley, R. Proteomics of *Naja kaouthia* venom from North East India and assessment of Indian polyvalent antivenom by third generation antivenomics. *J. Proteomics* **207**, 103463 (2019).
6. Laustsen, A. H. et al. Snake venomics of monocled cobra (*Naja kaouthia*) and investigation of human IgG response against venom toxins. *Toxicon* **99**, 23–35 (2015).
7. Tan, K. Y., Tan, C. H., Fung, S. Y. & Tan, N. H. Venomics, lethality and neutralization of *Naja kaouthia* (monocled cobra) venoms from three different geographical regions of Southeast Asia. *J. Proteomics* **120**, 105–125 (2015).
8. Chippaux, J.-P. Snakebite envenomation turns again into a neglected tropical disease! *J. Venomous Anim. Toxins Incl. Trop. Dis.* **23**, 38 (2017).
9. Hamza, M. et al. Clinical management of snakebite envenoming: future perspectives. *Toxicon* **X**, 100079 (2021).
10. Stone, S. F. et al. Immune response to snake envenoming and treatment with antivenom; complement activation, cytokine production and mast cell degranulation. *PLoS Negl. Trop. Dis.* **7**, e2326 (2013).
11. Warrell, D. A. & Williams, D. J. Clinical aspects of snakebite envenoming and its treatment in low-resource settings. *Lancet* **401**, 1382–1398 (2023).
12. Thumtecho, S., Burlet, N. J., Ljungars, A. & Laustsen, A. H. Towards better antivenoms: navigating the road to new types of snakebite envenomating therapies. *J. Venomous Anim. Toxins Incl. Trop. Dis.* **29**, e20230057 (2023).
13. Silva, A., Hodgson, W. & Isbister, G. Antivenom for neuromuscular paralysis resulting from snake envenoming. *Toxins* **9**, 143 (2017).
14. Khalek, I. S. et al. Synthetic development of a broadly neutralizing antibody against snake venom long-chain α-neurotoxins. *Sci. Transl. Med.* **16**, eadkt1867 (2024).
15. Laustsen, A. H. et al. In vivo neutralization of myotoxin II, a phospholipase A<sub>2</sub> homologue from *Bothrops asper* venom, using peptides discovered via phage display technology. *ACS Omega* **7**, 15561–15569 (2022).
16. Sørensen, C. V. et al. Antibody-dependent enhancement of toxicity of myotoxin II from *Bothrops asper*. *Nat. Commun.* **15**, 173 (2024).
17. Bailon Calderon, H. et al. Development of nanobodies against hemorrhagic and myotoxic components of *Bothrops atrox* snake venom. *Front. Immunol.* **11**, 655 (2020).
18. Wade, J. et al. Generation of multivalent nanobody-based proteins with improved neutralization of long α-neurotoxins from elapid snakes. *Bioconjugate Chem.* **33**, 1494–1504 (2022).
19. Tulika, T. et al. Phage display assisted discovery of a pH-dependent anti-cobra toxin antibody from a natural variable domain library. *Protein Sci.* **32**, e4821 (2023).
20. Ledsgaard, L. et al. Discovery and optimization of a broadly-neutralizing human monoclonal antibody against long-chain α-neurotoxins from snakes. *Nat. Commun.* **14**, 682 (2023).
21. Glanville, J. et al. Venom protection by broadly neutralizing antibody from a snakebite subject. Preprint at [bioRxiv https://doi.org/10.1101/2022.09.26.507364](https://doi.org/10.1101/2022.09.26.507364) (2022).
22. Alomran, N., Chinnappan, R., Alsolaiss, J., Casewell, N. R. & Zourob, M. Exploring the utility of ssDNA aptamers directed against snake venom toxins as new therapeutics for snakebite envenoming. *Toxins* **14**, 469 (2022).
23. Anand, A. et al. Complex target SELEX-based identification of DNA aptamers against *Bungarus caeruleus* venom for the detection of envenomation using a paper-based device. *Biosens. Bioelectron.* **193**, 113523 (2021).
24. Chen, Y.-J., Tsai, C.-Y., Hu, W.-P. & Chang, L.-S. DNA aptamers against Taiwan banded krait α-bungarotoxin recognize Taiwan cobra cardiotoxins. *Toxins* **8**, 66 (2016).
25. Savchik, E. Y. et al. Aptamer RA36 inhibits of human, rabbit, and rat plasma coagulation activated with thrombin or snake venom coagulases. *Bull. Exp. Biol. Med.* **156**, 44–48 (2013).
26. Dhiman, A. et al. Rational truncation of aptamer for cross-species application to detect krait envenomation. *Sci. Rep.* **8**, 17795 (2018).
27. Jenkins, T. et al. Toxin neutralization using alternative binding proteins. *Toxins* **11**, 53 (2019).
28. Romanovskis, P., Rosenberry, T. L., Cusack, B. & Spatola, A. F. in *Peptides: The Wave of the Future* (eds Lebl, M. & Houghten, R. A.) (Springer Netherlands, 2001).
29. Laustsen, A. H., Greiff, V., Karatt-Vellatt, A., Muylleermans, S. & Jenkins, T. P. Animal immunization, in vitro display technologies, and machine learning for antibody discovery. *Trends Biotechnol.* **39**, 1263–1273 (2021).
30. Damsbo, A. et al. A comparative study of the performance of *E. coli* and *K. phaffii* for expressing α-cobra toxin. *Toxicon* **239**, 107613 (2024).
31. Nessler, I. et al. Increased tumor penetration of single-domain antibody-drug conjugates improves in vivo efficacy in prostate cancer models. *Cancer Res.* **80**, 1268–1278 (2020).
32. Watson, J. L. et al. De novo design of protein structure and function with RFdiffusion. *Nature* **620**, 1089–1100 (2023).
33. Laustsen, A. H. et al. Pros and cons of different therapeutic antibody formats for recombinant antivenom development. *Toxicon* **146**, 151–175 (2018).
34. Utkin, Y. N. Last decade update for three-finger toxins: newly emerging structures and biological activities. *World J. Biol. Chem.* **10**, 17–27 (2019).
35. Kalogeropoulos, K. et al. A comparative study of protein structure prediction tools for challenging targets: snake venom toxins. *Toxicon* **238**, 107559 (2024).
36. Nys, M. et al. The molecular mechanism of snake short-chain α-neurotoxin binding to muscle-type nicotinic acetylcholine receptors. *Nat. Commun.* **13**, 4543 (2022).
37. Sappington, I. et al. Improved protein binder design using beta-pairing targeted RFdiffusion. Preprint at [bioRxiv https://doi.org/10.1101/2024.10.11.617496](https://doi.org/10.1101/2024.10.11.617496) (2024).
38. Bennett, N. R. et al. Improving de novo protein binder design with deep learning. *Nat. Commun.* **14**, 2625 (2023).
39. De La Rosa, G., Corrales-García, L. L., Rodriguez-Ruiz, X., López-Vera, E. & Corzo, G. Short-chain consensus alpha-neurotoxin: a synthetic 60-mer peptide with generic traits and enhanced immunogenic properties. *Amino Acids* **50**, 885–895 (2018).
40. Vázquez Torres, S. et al. De novo design of high-affinity binders of bioactive helical peptides. *Nature* **626**, 435–442 (2024).
41. Bekbosynova, A., Zharylgap, A. & Filchakova, O. Venom-derived neurotoxins targeting nicotinic acetylcholine receptors. *Molecules* **26**, 3373 (2021).
42. Miersch, S. et al. Synthetic antibodies block receptor binding and current-inhibiting effects of α-cobra toxin from *Naja kaouthia*. *Protein Sci.* **31**, e4296 (2022).
43. Antil-Delbeke, S. et al. Molecular determinants by which a long chain toxin from snake venom interacts with the neuronal α7-nicotinic acetylcholine receptor. *J. Biol. Chem.* **275**, 29594–29601 (2000).
44. Bourne, Y., Talley, T. T., Hansen, S. B., Taylor, P. & Marchot, P. Crystal structure of a Cbtx-AChBP complex reveals essential interactions between snake α-neurotoxins and nicotinic receptors. *EMBO J.* **24**, 1512–1522 (2005).
45. Hiu, J. J. & Yap, M. K. K. The myth of cobra venom cytotoxin: more than just direct cytolytic actions. *Toxicon X* **14**, 100123 (2022).
46. Chong, H. P., Tan, K. Y., Liu, B.-S., Sung, W.-C. & Tan, C. H. Cytotoxicity of venoms and cytotoxins from Asiatic cobras (*Naja kaouthia*, *Naja sumatrana*, *Naja atra*) and neutralization by antivenoms from Thailand, Vietnam, and Taiwan. *Toxins* **14**, 334 (2022).
47. Hiu, J. J., Fung, J. K. Y., Tan, H. S. & Yap, M. K. K. Unveiling the functional epitopes of cobra venom cytotoxin by immunoinformatics and epitope-omic analyses. *Sci. Rep.* **13**, 12271 (2023).
48. Dubovskii, P. V., Lesovoy, D. M., Dubinnyi, M. A., Utkin, Y. N. & Arsenieva, A. S. Interaction of the P-type cardiotoxin with phospholipid membranes. *Eur. J. Biochem.* **270**, 2038–2046 (2003).
49. Li, F., Shrivastava, I. H., Hanlon, P., Dagda, R. K. & Gasanoff, E. S. Molecular mechanism by which cobra venom cardiotoxins interact with the outer mitochondrial membrane. *Toxins* **12**, 425 (2020).
50. Konshina, A. G., Dubovskii, P. V. & Efremov, R. G. Structure and dynamics of cardiotoxins. *Curr. Protein Pept. Sci.* **13**, 570–584 (2012).
51. Kazandjian, T. D. et al. Convergent evolution of pain-inducing defensive venom components in spitting cobras. *Science* **371**, 386–390 (2021).
52. Jensen, A. *Design of Consensus Toxins and Their Use for the Discovery of Broadly Neutralizing Antibodies*. PhD thesis, DTU Bioengineering (2023).
53. Petras, D. et al. Snake venomics of African spitting cobras: toxin composition and assessment of congeneric cross-reactivity of the Pan-African EchiTAB-Plus-ICP antivenom by antivenomics and neutralization approaches. *J. Proteome Res.* **10**, 1266–1280 (2011).
54. Bartlett, K. E. et al. Dermonecrosis caused by spitting cobra snakebite results from toxin potentiation and is prevented by the repurposed drug varespladib. *Proc. Natl. Acad. Sci. USA* **121**, e2315597121 (2024).
55. Modahl, C. M., Mukherjee, A. K. & Mackessy, S. P. An analysis of venom ontogeny and prey-specific toxicity in the monocled cobra (*Naja kaouthia*). *Toxicon* **119**, 8–20 (2016).
56. Jenkins, T. P. & Laustsen, A. H. Cost of manufacturing for recombinant snakebite antivenoms. *Front. Bioeng. Biotechnol.* **8**, 703 (2020).
57. Laustsen, A. H. Recombinant snake antivenoms get closer to the clinic. *Trends Immunol.* **45**, 225–227 (2024).
58. Laustsen, A. H., Lohse, B., Lomonte, B., Engmark, M. & Gutiérrez, J. M. Selecting key toxins for focused development of elapid snake antivenoms and inhibitors guided by a toxicity score. *Toxicon* **104**, 43–45 (2015).
59. Nastopoulos, V., Kanellopoulos, P. N. & Tsernoglou, D. Structure of dimeric and monomeric erabutoxin a refined at 1.5 Å resolution. *Acta Crystallogr. D Biol. Crystallogr.* **54**, 964–974 (1998).
60. Dubovskii, P. V. et al. Impact of membrane partitioning on the spatial structure of an S-type cobra cytotoxin. *J. Biomol. Struct. Dyn.* **36**, 3463–3478 (2018).
61. Olsen, J. A., Balle, T., Gajhede, M., Ahring, P. K. & Kastrup, J. S. Molecular recognition of the neurotransmitter acetylcholine by an acetylcholine binding protein reveals determinants of binding to nicotinic acetylcholine receptors. *PLoS ONE* **9**, e91232 (2014).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

# Article

## Methods

### Cytotoxin consensus sequence design

Amino acid sequences for cytotoxins were collected from the UniProt website using family: "snake three-finger toxin family Short-chain sub-family Type IA cytotoxin sub-subfamily" as a query. The resultant 86 unique CTX sequences were subjected to multiple sequence alignments in Clustal Omega<sup>62</sup>. Using these alignments, a consensus sequence was designed to represent the most common amino acid at each position across the aligned sequences. In this process, each column of the sequence alignment was analysed to select the most frequent amino acid. In scenarios in which no single amino acid was dominant, a consensus symbol was used to represent a group of similar amino acids on the basis of their properties, such as charge or hydrophobicity. This approach allowed the representation of conserved biochemical properties rather than specific amino acid identities at positions with high variability.

### Secondary structure and block adjacency tensors

To generate the desired binder–target  $\beta$ -strand pairing interactions using RFdiffusion, fold-conditioning tensors describing single binder  $\beta$ -strands interacting with the target  $\beta$ -strands in a matrix format were supplied to RFdiffusion at inference. This information was supplied via two tensors: an  $[L,4]$  secondary one-hot tensor ( $0 = \alpha$ -helix,  $1 = \beta$ -strand,  $2 = \text{loop}$  and  $3 = \text{masked secondary structure identity}$ ) to indicate the secondary structure classification of each residue in the binder–target complex, and an  $[L,L,3]$  adjacency one-hot tensor ( $0 = \text{non-adjacent}$ ,  $1 = \text{adjacent}$  and  $2 = \text{masked adjacency}$ ) to indicate interacting partner residues for each residue in the binder–target complex. For the design of the binders described here, the secondary structure tensor indicated an entirely masked binder structure, with the exception of binder residues set to  $\beta$ -strand identities, whereas the adjacency tensor indicated a masked adjacency between binder–target residues, with the exception of the predefined strand residues being adjacent to the defined target strand residues.

### De novo 3FTx binder design using RFdiffusion

The crystal structures of ScNtx (PDB 7Z14) and  $\alpha$ -cobratoxin (PDB 1YI5) served as the inputs for RFdiffusion. In the case of the consensus cytotoxin, the AF2 model was used. Approximately 2,000 diffused designs were generated for each target, using the secondary structure and block adjacency tensors in the RFdiffusion model. The resulting backbone libraries underwent sequence design using ProteinMPNN, followed by FastRelax and AF2 + initial guess<sup>38</sup>. The resulting libraries were filtered on the basis of AF2 predicted aligned error (PAE)  $< 10$ , predicted local distance difference test (pLDDT)  $> 80$  and Rosetta Delta Delta G (ddg)  $< -40$ .

### Partial diffusion to optimize binders

The AF2 models of the highest-affinity designs for each toxin target were used as the inputs for partial diffusion. The models were subjected to 10 and 20 noise time steps out of a total of 50 time steps in the noise schedule and subsequently denoised ("diffuser.partial\_T" input values of 10 and 20). Approximately 2,000 partially diffused designs were generated for each target. The resulting library of backbones was sequence designed using ProteinMPNN after Rosetta FastRelax, followed by AF2 + initial guess<sup>38</sup>. The resulting libraries were filtered on the basis of AF2 PAE  $< 10$ , pLDDT  $> 80$  and Rosetta ddg  $< -40$ .

### Recombinant expression of ScNtx

ScNtx was recombinantly expressed from the methylotrophic yeast *Komagataella phaffii* (formerly known as *Pichia pastoris*). The ScNtx sequence was codon-optimized for expression in yeast and included an N-terminal His<sub>6</sub> tag, followed by a biotin acceptor peptide and a tobacco etch virus proteolytic site. The expression was performed as

described previously<sup>30</sup>. The culture medium was dialysed overnight against wash buffer (50 mM sodium phosphate buffer (pH 8.0) and 20 mM imidazole). Purification was carried out using an NGC chromatography system (Bio-Rad) with a 5 ml immobilized metal affinity chromatography (IMAC) nickel column (Bio-Rad). After loading, the column was washed with 5 column volumes of wash buffer to remove non-specifically bound proteins. The protein was then eluted using a gradient of 250 mM imidazole over 10 column volumes. Fractions with a high absorbance at 280 nm were pooled and dialysed against 50 mM sodium phosphate buffer (pH 8.0). Purity was assessed on SDS-PAGE to confirm the size. The protein solution was aliquoted and stored at  $-20^{\circ}\text{C}$  for further use.

### Toxins

$\alpha$ -Cobratoxin (L8114) was obtained from Latoxan. Cytotoxin from *N. pallida* was obtained from Sigma-Aldrich (217503).

### Venoms

Whole venoms for initial neutralization screening from *N. nigricollis* (CV01089563VEN) and *N. pallida* (CV01089566VEN) were obtained in lyophilized form from Amerigo Scientific. Catalogue numbers are provided in parentheses.

For in vitro neutralization experiments in human keratinocytes, whole venoms from *N. nigricollis* (L1327), *Naja nigricincta* (L1368), *Naja mossambica* (L1376), *Naja nubiae* (L1342), *Naja katiensis* (L1317), *Naja ashlei* (L1375) and *N. pallida* (L1321) were purchased in lyophilized form from Latoxan. Catalogue numbers are provided in parentheses.

For the in vivo anti-cytotoxin study, *N. nigricollis* venom was sourced from wild-caught Tanzanian specimens housed in the herpetarium of Liverpool School of Tropical Medicine.

### Gene construction of 3FTx binders

The designed protein sequences were optimized for expression in *E. coli*. Linear DNA fragments (eBlocks; Integrated DNA Technologies) encoding the design sequences contained overhangs suitable to cloning into the pETcon3 vector for yeast display (Addgene #45121) and LM627 vector for protein expression (Addgene #191551) through Golden Gate cloning.

### Yeast display screening

For yeast transformation, 50–60 ng of pETcon3, digested with NdeI and Xhol restriction enzymes, and 100 ng of the insert (eBlocks) were transformed into *Saccharomyces cerevisiae* EBY100 following the protocol described in a previous study<sup>63</sup>. EBY100 cultures were cultivated in C-Trp-Ura medium with 2% (w/v) glucose. To induce expression, yeast cells initially grown in the C-Trp-Ura medium with 2% (w/v) glucose were transferred to SGCA medium containing 0.2% (w/v) glucose and induced at  $30^{\circ}\text{C}$  for 16–24 h. After induction, the cells were washed with PBSF (phosphate-buffered saline (PBS) with 1% (w/v) bovine serum albumin) and labelled for 40 min with biotinylated toxin targets at room temperature using the without-avidity labelling condition<sup>63</sup>. Subsequently, the cells were washed, resuspended in PBSF and individually sorted on the basis of each unique design using a 96-well compatible autosampler in the Attune NxT Flow Cytometer (Thermo Fisher Scientific).

### Protein expression and purification in *E. coli* for 3FTx binders

Protein expression was conducted in 50 ml of Studier autoinduction medium supplemented with kanamycin, and cultures were grown overnight at  $37^{\circ}\text{C}$ . Cells were collected by centrifugation at 4,000×g for 10 min and resuspended in lysis buffer (100 mM Tris-HCl, 200 mM NaCl and 50 mM imidazole) supplemented with Pierce Protease Inhibitor Tablets (EDTA-free). Cell lysis was achieved by sonication using a Qsonica Q500 instrument with a four-pronged horn for 2.5 min ON total at an amplitude of 80%. Soluble fractions were clarified by

centrifugation at 14,000×g for 40 min and subsequently purified by affinity chromatography using Ni-NTA resin (Qiagen) on a vacuum manifold. Washes were performed using low-salt buffer (20 mM Tris-HCl, 200 mM NaCl and 50 mM imidazole) and high-salt buffer (20 mM Tris-HCl, 1,000 mM NaCl and 50 mM imidazole) before elution with elution buffer (20 mM Tris-HCl, 200 mM NaCl and 500 mM imidazole). Eluted protein samples were filtered and injected into an autosampler-equipped ÄKTA pure system on a Superdex S75 Increase 10/300 GL column at room temperature using SEC running buffer (20 mM Tris-HCl and 100 mM NaCl (pH 8)). Monodisperse peak fractions were pooled, concentrated using spin filters (3 kDa molecular weight cutoff; Amicon; Millipore Sigma) and stored at 4 °C before downstream characterizations. Protein concentrations were determined by measuring absorbance at 280 nm using a NanoDrop spectrophotometer (Thermo Fisher Scientific) using the molecular weights and extinction coefficients obtained from their amino acid sequences using the ProtParam tool.

### BLI binding experiments

BLI experiments were performed on an Octet RED96 (ForteBio) instrument, with streptavidin-coated tips (Sartorius item no. 18-5019). Buffer comprised 1× HBS-EP+ buffer (Cytiva BR100669) supplemented with 0.1% w/v bovine serum albumin. The tips were preincubated in buffer for at least 10 min before use. The tips were then sequentially incubated in biotinylated toxin target, buffer, designed binder and buffer.

### Affinity measurements by SPR

SPR experiments were conducted using a Biacore 8K instrument (Cytiva) and analysed using the accompanying evaluation software. Biotinylated α-cobratoxin was immobilized on a streptavidin sensor chip (Cytiva). For ScNtx and *N. pallida* cytotoxin, immobilization involved the activation of carboxymethyl groups on a dextran-coated chip through reaction with N-hydroxysuccinimide. The ligands were then covalently bonded to the chip surface by means of amide linkages, and the excess activated carboxyls were blocked with ethanalamine ([https://doi.org/10.1007/978-1-59745-523-7\\_20](https://doi.org/10.1007/978-1-59745-523-7_20)). Increasing concentrations of protein binders were flown over the chip in 1× HBS-EP+ buffer (Cytiva BR100669).

### Circular dichroism

The secondary structure content was evaluated by CD in a Jasco J-1500 CD spectrometer coupled to a Peltier system (EXOS) for temperature control. The experiments were performed on quartz cells with an optical path of 0.1 cm, covering a wavelength range of 200–260 nm. The CD signal was reported as molar ellipticity ( $\theta$ ). The thermal unfolding experiments were followed by a change in the ellipticity signal at 222 nm as a function of temperature. Proteins were denatured by heating at 1 °C min<sup>-1</sup> from 20 to 95 °C.

### Crystallization and structure determination

Crystallization experiments for the binder complex were conducted using the sitting drop vapour diffusion method. Crystallization trials were set up in 200 nl drops using a 96-well format by mosquito LCP from SPT Labtech. Crystal drops were imaged using the UVEX crystal plate hotel system by JANSi. Diffraction quality crystals for the LNG binder complex appeared in 1.5 M ammonium sulfate and 25% (v/v) glycerol in 2 weeks. Diffraction quality crystals for the SHRT binder appeared in 0.08 M sodium acetate trihydrate (pH 4.6), 1.6 M ammonium sulfate and 20% (v/v) glycerol. For CYTX\_B10-complex diffraction, quality crystals appeared in 0.1 M 2-(*N*-morpholino)ethanesulfonic acid (MES) (pH 6), 0.01 M zinc chloride, 20% (w/v) polyethylene glycol (PEG) 6000 and 10% (v/v) ethylene glycol. The crystals were flash-cooled in liquid nitrogen before being transported to the synchrotron for diffraction experiments.

The diffraction data were collected at the National Synchrotron Light Source II Beamline AMX (17-ID-1). X-ray intensities and data reduction were evaluated and integrated using XDS<sup>64</sup> and merged/scaled using Pointless/Aimless in the CCP4i2 Program Suite<sup>65</sup>. The structure was determined by molecular replacement using a model designed using Phaser<sup>66</sup>. Following molecular replacement, the model was improved and refined using Phenix<sup>67</sup>. Model building was performed using Coot<sup>68</sup> in between refinement cycles. The final model was evaluated using MolProbity<sup>69</sup>. Data collection and refinement statistics are reported in Extended Data Table 1. The final atomic coordinates, mmCIF and structural factors were deposited in the PDB with accession codes 9BK5, 9BK6 and 9BK7, respectively.

### In vitro neutralization using electrophysiology

Human-derived rhabdomyosarcoma RD cells (American Type Culture Collection) endogenously expressing the muscle-type nAChR were used for electrophysiology experiments<sup>20</sup>. Planar whole-cell patch-clamp recordings were conducted on a Qube automated electrophysiology platform (Sophion Bioscience) with 384-channel patch chips (patch hole resistance  $2.00 \pm 0.02 \text{ M}\Omega$ ), following the protocol detailed in a previous study<sup>20</sup>. Protein binders were preincubated with approximately one 80% inhibitory concentration ( $IC_{50}$ ) of α-cobratoxin or ScNtx at various toxin-to-binder molar ratios (1:1, 1:3, 1:9 and 1:27) and then added to the cells. The ability of the toxin to inhibit an acetylcholine (ACh; 70 μM) response in the presence or absence of binders was normalized to the full ACh response, averaged in each group ( $n = 16$ ) and represented in a non-cumulative concentration-response plot. We analysed data using Sophion Analyzer v.6.6.70 (Sophion Bioscience) and GraphPad Prism v.10.1.1 (GraphPad Software).

### Initial neutralization screening of whole venoms using cell viability assay

HEK293T cells were cultured in Dulbecco's modified Eagle's medium (Gibco) supplemented with 10% fetal bovine serum at 37 °C and 5% CO<sub>2</sub>. Cells were subjected to commercial whole venoms from *N. pallida* (34 μg ml<sup>-1</sup>) and *N. nigricollis* (42 μg ml<sup>-1</sup>), either in the absence or presence of 1:1 or 5:1 molar ratio of toxin:binder. Buffer and binder-only controls were run in parallel, and all samples were preincubated for 30 min at room temperature before addition to HEK293T cells. To determine the percentage of viable cells, RealTime-Glo MT Cell Viability Assay (Promega) was performed according to the manufacturer's protocol. Experiments were performed in triplicate, and the results were expressed as mean ± s.d.

### In vitro neutralization of whole venoms using cell viability assay

N/TERT-immortalized keratinocytes were cultured as described previously<sup>70</sup>. After determining the  $IC_{50}$  for seven venoms of *Afronaja* snakes, N/TERT cells were subjected to twice the  $IC_{50}$  of each venom, either in the absence or presence of a 1:5 molar ratio of venom:binder. Buffer and binder-only controls were run in parallel, and all samples were preincubated (30 min at 37 °C) before addition to N/TERT cells. To determine the percentage of viable cells, the CellTiter-Glo Luminescent Cell Viability Assay (Promega) was performed according to the manufacturer's protocol. Experiments were performed in triplicates, and results were expressed as mean ± s.d.

### LD<sub>50</sub> determinations for α-neurotoxins

All assays used male non-Swiss albino mice (20–30 g), and all doses were mass adjusted. The toxins assayed were α-cobratoxin (7,820 Da, from *N. kaouthia* venom obtained from Latoxan S.A.S.) and the short-chain neurotoxin ScNtx (8,944 Da, recombinantly expressed). The toxins were solubilized in PBS at 1.0 mg ml<sup>-1</sup> and then diluted in PBS as needed. For toxin LD<sub>50</sub> determination, five doses with three mice per dose were used, and a 100 μl bolus was injected intraperitoneally in the right lower abdominal region; controls received only PBS. The injected mice

# Article

were observed for the first 2 h and then again at 24 h. LD<sub>50</sub> values were calculated using the Quest Graph LD<sub>50</sub> Calculator<sup>71</sup>.

## In vivo neurotoxicity protein binder protection assays

In the preincubation experiments, three LD<sub>50</sub> values of the toxins ( $\alpha$ -cobratoxin, 0.294  $\mu\text{g g}^{-1}$  mouse; ScNtx, 0.261  $\mu\text{g g}^{-1}$  mouse) were mixed with a ten-fold molar excess of their respective protein binders in PBS and incubated at room temperature for 30 min before intraperitoneal administration. Groups of five mice were injected with the binder:toxin mixture and observed at 2 and 24 h. In rescue experiments, toxins (three LD<sub>50</sub> values) were administered intraperitoneally 15 or 30 min before the corresponding binder, given intraperitoneally at either ten-fold or five-fold molar excess to groups of five mice. Protection against lethality was measured as per cent mortality at 24 h.

## In vivo dermonecrosis protein binder protection assays

CD1 male mice (18–20 g; Charles River Laboratories) were acclimated for 1 week before experimentation in specific pathogen-free conditions. The holding room conditions were 23 °C with 45–65% humidity and 12/12 h light cycles (350 lux). Mice were housed in Tecniplast GM500 cages (floor area of 501 cm<sup>2</sup>) containing 120 g LIGNOCEL wood fibre bedding (JRS) and Z-nest biodegradable paper-based material for nesting and environmental enrichment (red house, clear polycarbonate tunnel and loft). The mice had ad libitum access to irradiated PicoLab food (LabDiet) and reverse osmosis water in an automatic water system. The animals were split into cages (experimental units) upon arrival, and no further randomization was performed.

All mice were pretreated with 5 mg kg<sup>-1</sup> morphine (injected subcutaneously) before receiving intradermal injections in a 100  $\mu\text{l}$  volume into the ventral abdominal region (rear side flank region). A venom-only control group of five mice received 63  $\mu\text{g}$  of *N. nigriceps* (Tanzania) venom (dissolved in PBS). For protection assays, crude venom was preincubated (30 min at 37 °C) with varying cytotoxin:binder ratios of 1:1, 1:2.5 and 1:5 before injection ( $n = 3$ ) (ratios estimated from the proportion of cytotoxin in the venom). Before this, the control group ( $N = 3$ ) received injections of cytotoxin binder alone (278  $\mu\text{M}$ , equivalent to the 1:5 cytotoxin:binder dose) to check tolerance of the cytotoxin binder. For sample size,  $N = 3$  was used for groups receiving the cytotoxin binder because this was a pilot experiment.  $N = 5$  was used for the venom-only control group because of the variation in lesion size, which is the size recommended by the World Health Organization. In total, 17 mice were used. No inclusion or exclusion criteria were used during the experiment, and all data points were used in the analysis. No strategy was used to control confounders. All experimenters were aware of the group allocation during the experiment and analysis.

After 72 h, the mice were euthanized with increasing concentrations of CO<sub>2</sub>, and the lesions were excised. The outcome measured was the lesion size. Photographs of the lesions were taken using a digital camera immediately after excision, and the severity and size of the dermonecrotic lesions were determined using Venom Induced Dermonecrosis Analysis tool (VIDAL)<sup>72</sup>.

## Ethical approval

Animal experiments for in vivo neurotoxicity assays were conducted at the University of Northern Colorado under protocol 2303D-SM-S-26, approved by the University of Northern Colorado Institutional Animal Care and Use Committee (UNC-IACUC), in accordance with Government Principles, Public Health Policy, US Department of Agriculture Animal Welfare Act and the Guide for the Care and Use of Laboratory Animals.

Animal experiments for in vivo dermonecrosis assays were approved by the Animal Welfare and Ethics Review Board of the Liverpool School of Tropical Medicine and the University of Liverpool, and conducted under the UK Home Office project licence P58464F90 in accordance with the UK Animal (Scientific Procedures) Act 1986.

## Cell line development, acquisition and authentication

HEK293T cells (American Type Culture Collection CRL-3216) and N/TERT-immortalized keratinocytes, provided by E. O'Toole (Queen Mary University of London), were authenticated by means of morphological assessment and tested for mycoplasma contamination.

## Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

## Data availability

Atomic models of the snake toxin binders have been deposited in the PDB. These include the apo-state structure of the SHRT design (PDB 9BK7) (Fig. 3a), the holo-state structure of the LNG design in complex with  $\alpha$ -cobratoxin (PDB 9BK5) (Fig. 3b) and the CYTX\_B10 design in complex with *N. pallida* cytotoxin (PDB 9BK6) (Fig. 3c).

## Code availability

Code explanation and examples of binder design using RFdiffusion can be found at <https://github.com/RosettaCommons/RFdiffusion#binder-design>.

62. Sievers, F. et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. *Mol. Syst. Biol.* **7**, 539 (2011).
63. Cao, L. et al. Design of protein-binding proteins from the target structure alone. *Nature* **605**, 551–560 (2022).
64. Kabsch, W. XDS. *Acta Crystallogr. D Biol. Crystallogr.* **66**, 125–132 (2010).
65. Winn, M. D. et al. Overview of the CCP4 suite and current developments. *Acta Crystallogr. D Biol. Crystallogr.* **67**, 235–242 (2011).
66. McCoy, A. J. et al. Phaser crystallographic software. *J. Appl. Crystallogr.* **40**, 658–674 (2007).
67. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr. D Biol. Crystallogr.* **66**, 213–221 (2010).
68. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. *Acta Crystallogr. D Biol. Crystallogr.* **60**, 2126–2132 (2004).
69. Williams, C. J. et al. MolProbity: more and better reference data for improved all-atom structure validation. *Protein Sci.* **27**, 293–315 (2018).
70. Pucca, M. B. et al. Unity makes strength: exploring intraspecies and interspecies toxin synergism between phospholipases A<sub>2</sub> and cytotoxins. *Front. Pharmacol.* **11**, 611 (2020).
71. LD50 Calculator. *AAT Biotech* [www.aatbio.com/tools/ld50-calculator](http://www.aatbio.com/tools/ld50-calculator) (2015).
72. Laprade, W. et al. Machine-learning guided Venom Induced Dermonecrosis Analysis tool: VIDAL. *Sci. Rep.* **13**, 21662 (2023).

**Acknowledgements** We thank A. Saragovi, F. A. Davila Hernandez, L. Mihaljević, Y. Flores Bueso and K. Shelley for helpful discussions on this study. This study was supported with funds provided by the Open Philanthropy Project Improving Protein Design Fund (S.V.T., R.J.R. and D.B.), Washington State General Operating Fund supporting the Institute for Protein Design (I.S.), Audacious Project at the Institute for Protein Design (A.S.P., M.A., H.L.H. and D.B.) and Howard Hughes Medical Institute (D.B.). E.M. was supported by the Novo Nordisk Foundation (GR032004). T.P.J. acknowledges support from the Alliance programme under the EuroTech Universities Alliance agreement. M.B.V. received funding from the European Union's Horizon 2020 research and innovation programme under Marie Skłodowska-Curie grant agreement no. 899987. N.R.C. acknowledges support from Wellcome Trust (grant nos. 221708/Z/20/Z and 223619/Z/21/Z). S.P.M. acknowledges support from the National Science Foundation (grant no. 2307044). This research was funded in part by the Wellcome Trust. For the purpose of open access, the authors have applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. We acknowledge the Biomedical Services Unit provided by the Liverpool Shared Research Facilities, Faculty of Health and Life Sciences, University of Liverpool. We are grateful to P. Rowley (Liverpool School of Tropical Medicine) for the care of, and venom extraction from, some of the snakes used in this study. Crystallographic data were collected at the National Synchrotron Light Source II Beamline 17-ID-1 (AMX). The Center for BioMolecular Structure is primarily supported by the NIH-NIGMS through a Center Core P30 Grant (P30GM133893) and by the Department of Energy Office of Biological and Environmental Research (KP1607011). NSLS2 is a US Department of Energy Office of Science User Facility operated under contract no. DE-SC0012704. This publication resulted from the data collected using the beamtime obtained through the NECAT BAG proposal no. 311950. A.H.L. is supported by a grant from the European Research Council under the European Union's Horizon 2020 research and innovation programme (850974) and a grant from Wellcome (221702/Z/20/Z).

**Author contributions** D.B., T.P.J., T.J.A.F. and S.V.T. conceptualized the project. D.B. and T.P.J. provided directions for this study. S.V.T. designed, screened and experimentally characterized all snake toxin protein binders shown in this paper. I.S. developed the  $\beta$ -strand

pairing method for designing the  $\alpha$ -neurotoxin-binding proteins. S.P.M. performed animal testing for the  $\alpha$ -neurotoxin-binding proteins. S.K.M., I.A.C., E.P.C., R.J.E. and N.R.C. conducted animal testing for the cytotoxin protein binder. M.B.V. and N.J.B. conducted patch-clamp experiments to validate the functional neutralization of the  $\alpha$ -neurotoxin-binding proteins. M.D.O., M.B.V. and H.L.H. assisted with affinity binding measurements using BLI for the  $\alpha$ -neurotoxin-binding proteins. T.P.J. and J.L. designed the consensus cytotoxin. S.V.T. and E.M. designed the experimental protocol to evaluate cytotoxicity in HEK293T cells. S.A., N.J.B., J.D., M.A. and R.S. supported the functional assay screening to validate the performance of the cytotoxin binders. E.R. recombinantly expressed and purified the ScNtx toxin. S.R.G. and A.M. performed additional scaled-up protein purification. A.K.B., A.K., E.B. and S.V.T. obtained all crystal structures shown in this paper. R.J.R. supported with affinity binding measurements using SPR for all toxin-binding proteins. A.H.L., A.S.P., L.S. and T.J.A.F. provided research support and supervision. All authors reviewed and accepted the paper.

**Competing interests** D.B., S.V.T., T.P.J., M.B.V., S.P.M., S.K.M., N.R.C., E.M., I.S., A.K.B. and A.K. are inventors on a provisional patent application submitted by the University of Washington for the design and composition of the proteins created in this study.

**Additional information**

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41586-024-08393-x>.

**Correspondence and requests for materials** should be addressed to Timothy P. Jenkins or David Baker.

**Peer review information** *Nature* thanks Pedro Alexandrino Fernandes, Alexander Pritzel and Kartik Sunagar for their contribution to the peer review of this work. Peer reviewer reports are available.

**Reprints and permissions information** is available at <http://www.nature.com/reprints>.

# Article

**Extended Data Table 1 | Data collection and refinement statistics (molecular replacement)**

|                                     | LNG binder (holo) (PDB ID: 9BK5)    | B10_CYTX binder (holo) (PDB ID: 9BK6) | SHRT_binder (apo) (PDB ID: 9BK7)    |
|-------------------------------------|-------------------------------------|---------------------------------------|-------------------------------------|
| <b>Data collection</b>              |                                     |                                       |                                     |
| Space group                         | $I\bar{4}_1 2 2$                    | $P 2_1 2_1 2_1$                       | $I\bar{4}_1 2 2$                    |
| Cell dimensions<br>$a, b, c$ (Å)    | 77.79, 77.79, 173.52                | 34.56, 63.66, 77.72                   | 75.33, 75.33, 108.34                |
| $\alpha, \beta, \gamma$ (°)         | 90, 90, 90                          | 90, 90, 90                            | 90, 90, 90                          |
| Resolution (Å)                      | 34.06 - 2.68 (2.85 - 2.68)          | 33.17 - 2.00 (2.05 - 2.00)            | 32.17 - 2.58 (2.84 - 2.58)          |
| $R_{\text{merge}}$                  | 0.105 (3.172)                       | 0.088 (0.599)                         | 0.246 (1.069)                       |
| $I / \sigma I$                      | 17.12 (1.08)                        | 10.4 (2.6)                            | 13.30 (4.13)                        |
| Completeness (%)                    | 99.86 (99.53)                       | 99.7 (99.7)                           | 99.83 (99.92)                       |
| Redundancy                          | 24.3 (25.8)                         | 6.4 (6.2)                             | 24.6 (25.2)                         |
| <b>Refinement</b>                   |                                     |                                       |                                     |
| Resolution (Å)                      | 34.06 - 2.68 (2.85 - 2.68)          | 33.17 - 2.00 (2.05 - 2.00)            | 32.17 - 2.58 (2.84 - 2.58)          |
| No. reflections                     | 7836 (1264)                         | 12047 (2928)                          | 5179 (1262)                         |
| $R_{\text{work}} / R_{\text{free}}$ | 0.2387 (0.3049)/<br>0.2681 (0.3349) | 0.2496 (0.3301)/<br>0.2850 (0.4167)   | 0.1970 (0.2954)/<br>0.2235 (0.3560) |
| No. atoms                           |                                     |                                       |                                     |
| Protein                             | 1118                                | 1241                                  | 739                                 |
| Ligand/ion                          | n/a                                 | n/a                                   | n/a                                 |
| Water                               | n/a                                 | 57                                    | n/a                                 |
| $B$ -factors                        |                                     |                                       |                                     |
| Protein                             | 101.38                              | 48.61                                 | 67.50                               |
| Ligand/ion                          | n/a                                 | n/a                                   | n/a                                 |
| Water                               | n/a                                 | 48.81                                 | n/a                                 |
| R.m.s. deviations                   |                                     |                                       |                                     |
| Bond lengths (Å)                    | 0.003                               | 0.002                                 | 0.004                               |
| Bond angles (°)                     | 0.55                                | 0.45                                  | 0.62                                |

\*Single Crystal used for each data collection. \*Values in parentheses are for highest-resolution shell.

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
  - Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted
  - Give  $P$  values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection RFdiffusion 1.0.0, AlphaFold2, ,ProteinMPNN, CCP4i2 program suite

Data analysis Matplotlib 3.6.2, SciPy 1.9.3, Seaborn 0.11.2, PyMOL 2.5.0, Phaser, COOT Gtkt+2: 0.9.8.95, Sophion Analyzer v6.6.70, GraphPad Prism v10.1.1, VIDAL1

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

Atomic models of the snake toxin binders have been deposited in the Protein Data Bank. These include the apo-state structure of the SHRT design (PDB ID: 9BK7, Fig. 3a), the holo-state structure of the LNG design in complex with  $\alpha$ -cobratoxin (PDB ID: 9BK5, Fig. 3b), and the CYTX\_B10 design in complex with Naja pallida cytotoxin (PDB ID: 9BK6, Fig. 3c).

# Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

|                 |  |
|-----------------|--|
| Sample size     | We used three animals per dose to determine LD50 values, minimizing animal use while demonstrating proof-of-concept for neutralizing snake venom toxins with our de novo protein binders. Determining precise LD50 values is not relevant here, as our proteins are experimental. In our in vivo protection assay, we used five mice. A small-scale trial with a well-defined endpoint, such as overall mortality, effectively tests preclinical hypotheses and demonstrates the therapeutic potential of our binders to neutralize lethal snake toxin |
| Data exclusions | None   |
| Replication     | Each dataset contains many (n reported in figure legends) independent measurements.  |
| Randomization   | Snake venom has a well-defined, immediate toxic effect, and antivenom neutralization follows a clear biological pathway. Because the biological response to venom and antivenom is relatively predictable, randomization may not add significant value to the validity of the experiment   |
| Blinding        | N/A (all analysis was automated)   |

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

| Materials & experimental systems    |                               | Methods                             |                        |
|-------------------------------------|-------------------------------|-------------------------------------|------------------------|
| n/a                                 | Involved in the study         | n/a                                 | Involved in the study  |
| <input checked="" type="checkbox"/> | Antibodies                    | <input checked="" type="checkbox"/> | ChIP-seq               |
| <input type="checkbox"/>            | Eukaryotic cell lines         | <input checked="" type="checkbox"/> | Flow cytometry         |
| <input checked="" type="checkbox"/> | Palaeontology and archaeology | <input checked="" type="checkbox"/> | MRI-based neuroimaging |
| <input type="checkbox"/>            | Animals and other organisms   |                                     |                        |
| <input checked="" type="checkbox"/> | Human research participants   |                                     |                        |
| <input checked="" type="checkbox"/> | Clinical data                 |                                     |                        |
| <input checked="" type="checkbox"/> | Dual use research of concern  |                                     |                        |

## Eukaryotic cell lines

Policy information about [cell lines](#)

|  |  |
|--|--|
| Cell line source(s)  | HEK293T were obtained from ATCC, N/TERT immortalized keratinocytes were kindly provided by Edel O'Toole from the Queen Mary University of London |
| Authentication   | Morphology check by microscope   |
| Mycoplasma contamination   | All cell lines tested negative for mycoplasma contamination  |
| Commonly misidentified lines<br>(See <a href="#">ICLAC</a> register) | N/A  |

## Animals and other organisms

Policy information about [studies involving animals; ARRIVE guidelines](#) recommended for reporting animal research

|                    |  |
|--------------------|--|
| Laboratory animals | NSA CD1 male mice (Charles River, 18-20 g) |
| Wild animals       | No wild animals were used in the study     |

|                         |   |
|-------------------------|---|
| Field-collected samples | N/A   |
| Ethics oversight        | <p>Animal experiments for in vivo neurotoxicity assays were conducted at the University of Northern Colorado under protocol 2303D-SM-S-26, approved by the UNC Institutional Animal Care and Use Committee (UNC-IACUC), in accordance with Government Principles, Public Health Policy, USDA Animal Welfare Act, and the Guide for the Care and Use of Laboratory Animals.</p> <p>Animal experiments for in vivo dermonecrosis assays were approved by the Animal Welfare and Ethical Review Boards of the Liverpool School of Tropical Medicine and the University of Liverpool, and conducted under UK Home Office project license P58464F90 in accordance with the UK Animal (Scientific Procedures) Act 1986.</p> |

Note that full information on the approval of the study protocol must also be provided in the manuscript.